Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 9:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 1,836 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Psychosis Clear all
Completed Not applicable Interventional

Quetiapine vs Haloperidol Decanoate for the Long Term Treatment of Schizophrenia and Schizoaffective Disorder

NCT00018642
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
quetiapine, haloperidol decanoate
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 21, 2009 · Synced Oct 19, 2026, 9:59 PM EDT
Completed Phase 4 Interventional Results available

Antipsychotic Discontinuation in Alzheimer's Disease

NCT00417482
View directory record Official record
Conditions
Alzheimer Disease, Psychotic Disorders, Agitation, Aggression
Interventions
risperidone
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
50 Years to 95 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
7
States / cities
Tuscaloosa, Alabama • Los Angeles, California • Norwalk, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2013 · Synced Oct 19, 2026, 9:59 PM EDT
Recruiting Not applicable Interventional

Targeting Processing Speed Deficits to Improve Social Functioning and Lower Psychosis Risk

NCT05131035
View directory record Official record
Conditions
Psychosis, Prodromal Schizophrenia, Prodromal Symptoms
Interventions
SCORES (Specific COgnitive Remediation with Support)
Behavioral
Lead sponsor
Northwell Health
Other
Eligibility
14 Years to 20 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 19, 2026, 9:59 PM EDT
Completed Phase 4 Interventional

Feasibility of Providing Cognitive Remediation to People With Schizophrenia in a Clinical Network

NCT00930150
View directory record Official record
Conditions
Schizophrenia
Interventions
Targeted cognitive training, Computer control, Bridging groups, Health and wellness groups
Behavioral
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
9
States / cities
New Haven, Connecticut • Atlanta, Georgia • Augusta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2011 · Synced Oct 19, 2026, 9:59 PM EDT
Completed Phase 3 Interventional Results available

Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients

NCT02109562
View directory record Official record
Conditions
Schizophrenia
Interventions
RBP-7000, Placebo, Risperidone
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
32
States / cities
Little Rock, Arkansas • Springdale, Arkansas • Cerritos, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2018 · Synced Oct 19, 2026, 9:59 PM EDT
Withdrawn Phase 3 Interventional

Brexpiprazole (OPC 34712) Trial in the Treatment of Adults With Major Depressive Disorder and Irritability

NCT02212613
View directory record Official record
Conditions
Major Depressive Disorder and Irritability
Interventions
Brexpiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 7, 2016 · Synced Oct 19, 2026, 9:59 PM EDT
Completed Phase 3 Interventional Results available

A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With Schizophrenia

NCT05693935
View directory record Official record
Conditions
Schizophrenia
Interventions
TV-44749, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
675 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
53
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 38 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 19, 2026, 9:59 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Biomarker Strategies for Medication-Enhanced Cognitive Training in Schizophrenia

NCT01555697
View directory record Official record
Conditions
Schizophrenia
Interventions
Memantine, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2022 · Synced Oct 19, 2026, 9:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

THC and Ketamine Effects in Humans: Relation to Neural Oscillations and Psychosis

NCT04199468
View directory record Official record
Conditions
Cannabis, Ketamine
Interventions
Active Delta-9-THC, Placebo Delta-9-THC, Active Ketamine, Placebo Ketamine
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 45 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 25, 2024 · Synced Oct 19, 2026, 9:59 PM EDT
Completed Phase 1 Interventional

Enhancing Motivation To Quit Smoking In Smokers With Serious Mental Illness

NCT00500695
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Motivational Interviewing, Psychoeducation
Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 18, 2017 · Synced Oct 19, 2026, 9:59 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Pharmacological Modulation of Hippocampal Activity in Psychosis 2

NCT04559529
View directory record Official record
Conditions
Schizophrenia; Psychosis
Interventions
Levetiracetam (LEV) 500 mg, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Oct 19, 2026, 9:59 PM EDT
Completed Phase 1 Interventional

The Effects AZD8529 on Cognition and Negative Symptoms in Schizophrenics

NCT00986531
View directory record Official record
Conditions
Schizophrenia
Interventions
AZD8529, Placebo to match AZD8529
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 1, 2011 · Synced Oct 19, 2026, 9:59 PM EDT
Completed Phase 1 Interventional

Trial to Study the Effect of CVL-231 on 24-Hour Ambulatory Blood Pressure in Participants With Schizophrenia

NCT05245539
View directory record Official record
Conditions
Blood Pressure, Schizophrenia
Interventions
CVL-231
Drug
Lead sponsor
Cerevel Therapeutics, LLC
Industry
Eligibility
30 Years to 60 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
10
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Long Beach, California + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2022 · Synced Oct 19, 2026, 9:59 PM EDT
Completed No phase listed Observational

Side Effects of Antipsychotic Medications

NCT00363181
View directory record Official record
Conditions
Insulin Resistance, Metabolic Syndrome X, Schizophrenia and Disorders With Psychotic Features, Mood Disorders, Psychotic Disorders
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
30 Years to 66 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 22, 2021 · Synced Oct 19, 2026, 9:59 PM EDT
Completed Phase 1 Interventional

A Study of the Safety, Tolerability and Pharmacokientics of RO5545965 in Patients With Schizophrenia on Risperidone

NCT02019329
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, RO5545965, risperidone
Other · Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 19, 2026, 9:59 PM EDT
Recruiting Not applicable Interventional

Taking Action for College Students

NCT06700902
View directory record Official record
Conditions
Major Depressive Disorder, Bipolar Disorder, Schizophrenia
Interventions
Taking Action
Behavioral
Lead sponsor
Temple University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Oct 19, 2026, 9:59 PM EDT
Completed Not applicable Interventional Results available

Targeting Physical Health in Schizophrenia: Physical Activity Can Enhance Life Randomized Control Trial

NCT04173572
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Brief Psychotic Disorder, Schizophreniform Disorders, Unspecified Schizophrenia Spectrum and Other Psychotic Disorder
Interventions
PACE-Life, Exercise Intervention
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Oct 19, 2026, 9:59 PM EDT
Completed Phase 2 Interventional Results available

Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetic/Efficacy

NCT01677377
View directory record Official record
Conditions
Schizophrenia
Interventions
Risperidone, RBP-7000
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Little Rock, Alaska • Long Beach, California
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Oct 19, 2026, 9:59 PM EDT
Completed Phase 3 Interventional Results available

Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia

NCT00641745
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Lurasidone HCl, Risperidone
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
629 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
41
States / cities
Little Rock, Arkansas • Anaheim, California • Cerritos, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2015 · Synced Oct 19, 2026, 9:59 PM EDT
Completed Phase 2 Interventional Results available

Effects of Pentazocine Versus Lorazepam on Manic Symptoms

NCT00431184
View directory record Official record
Conditions
Bipolar Disorder, Schizoaffective Disorder, Manic Disorder, Mania, Manic State
Interventions
Pentazocine, Lorazepam
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 6, 2019 · Synced Oct 19, 2026, 9:59 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effect of Transcranial Magnetic Stimulation on Memory

NCT00105118
View directory record Official record
Conditions
Healthy, Healthy Volunteer, HV
Interventions
Magstim Super Rapid Magnetic Stimulator
Device
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 19, 2026, 9:59 PM EDT
Completed Phase 1 Interventional Results available

Lurasidone Pediatric Pharmacokinetics Study

NCT01620060
View directory record Official record
Conditions
Schizophrenia, Autism
Interventions
Lurasidone
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
10
States / cities
Little Rock, Arkansas • Springdale, Arkansas • Murrieta, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2016 · Synced Oct 19, 2026, 9:59 PM EDT
Completed Not applicable Interventional Results available

Decision Support for Smoking Cessation in Young Adults With Severe Mental Illness

NCT01779440
View directory record Official record
Conditions
Mental Illness, Tobacco Smoking, Psychotic Disorders
Interventions
Electronic Decision Support System
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 30 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
3
States / cities
Manchester, New Hampshire • Nashua, New Hampshire • Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Oct 19, 2026, 9:59 PM EDT
Completed Not applicable Interventional Results available

Life Goals Collaborative Care to Improve Health Outcomes in Mental Disorders

NCT01487668
View directory record Official record
Conditions
Bipolar Disorder, Schizophrenia, Major Depressive Disorder, Schizoaffective Disorder, Cardiovascular Disease Risk
Interventions
Life Goals Collaborative Care
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 99 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 22, 2016 · Synced Oct 19, 2026, 9:59 PM EDT